ClinConnect ClinConnect Logo
Search / Trial NCT07066527

Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Jul 4, 2025

Trial Information

Current as of November 07, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new type of foam treatment called polylauric alcohol more stable foam for people with venous malformations in the head and neck area. Venous malformations are abnormal clusters of veins that can cause swelling or discomfort. The goal of the study is to see if this new foam works better and is as safe as the ordinary foam treatments currently used. This could help doctors find better ways to treat these vein problems.

People aged 14 to 60 years old who have been diagnosed with head and neck venous malformations through medical exams may be eligible to join, as long as they are not pregnant or planning pregnancy, and do not have serious health issues like uncontrolled heart disease, diabetes, or high blood pressure. If you join, you will be asked to give your consent and follow the treatment plan, including attending regular follow-up visits. The study is currently looking for participants, and those interested should be willing to cooperate fully throughout the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 14-60 years of age, sex unlimited (except pregnant women or those preparing for pregnancy)
  • 2. Clinical diagnosis and imaging () were consistent with head and neck venous malformations
  • 3. Participants volunteered to participate in the trial and signed an informed consent form.
  • Exclusion Criteria:
  • 1. People with serious systemic diseases, including heart disease, high blood pressure, diabetes, etc. , that are not under control. Heart Attack: 1. Recent frequent attacks of angina. 2. Recent history of myocardial infarction 3. Cardiac function grade iii-iv or with symptoms of sitting breathing, cyanosis, jugular venous distension, lower limb edema, etc. . 4. Heart disease complicated with hypertension 5. Type II or III Type II atrioventricular block, double bundle branch block, as syndrome, diabetes: blood sugar control in 8.88 mmol/L above, hypertension: after taking medicine blood pressure can not be controlled in the normal range namely systolic pressure below 140 mmhg, diastolic pressure below 90 mmhg)
  • 2. Patients who are unable to follow up on time;
  • 3. Persons who are mentally ill or have mental disorders;
  • 4. The patient or his/her authorized person is unwilling to sign a written informed consent or comply with the protocol

About Qilu Hospital Of Shandong University

Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.

Locations

Jinan, Shandong, China

Patients applied

0 patients applied

Trial Officials

shaohua liu, Doctoral

Principal Investigator

Shandong University Qilu Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported